Skip to content

Preferred Stock at other companies

Sarepta Therapeutics, Inc. logo
Sarepta Therapeutics, Inc.SRPT
$0
Celldex Therapeutics logo
Celldex TherapeuticsCLDX
$0
Dyne Therapeutics, Inc. logo
Dyne Therapeutics, Inc.DYN
$0
LeMaitre Vascular logo
LeMaitre VascularLMAT
$0
Cytokinetics logo
CytokineticsCYTK
$0
Catalyst Pharmaceutical logo
Catalyst PharmaceuticalCPRX
$0

Other financials

Income statement

See full
Revenue--100%
Operating income-$36.8M-47.2%
Net income-$33.9M-39.2%
EPS (diluted)-$0.59-11.3%

Balance sheet

See full
Cash & equivalents$105.4M+266%
Total debt$14.8M+1,083%
Total equity$278.7M+118%
Total assets$326.3M+112%

Cash flow

See full
Operating cash flow-$29.3M-355%
CapEx$5.1M+472%
Free cash flow-$34.4M-369%

Valuation

See full
Market cap$1.71B+303%

Profitability

See full
Operating margin-778.8%-1,038pp
Net margin-736.6%-981pp
FCF margin-563.9%-954pp

Returns & leverage

See full
Return on equity-56.4%-11.3pp
Debt / equity0.1×0.0×
Current ratio8.4×+1.9×

Where this comes from

Reported directly by Capricor Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:PreferredStockValue.

The official record: Capricor Therapeutics’s 10-Q, filed November 13, 2020, on SEC EDGAR. View the filing →

Questions, answered.

What does preferred stock mean?
Equity securities with priority over common stock for dividends and liquidation proceeds, but typically without voting rights.